SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Conclusions
  7. References

The aim of the study was to verify whether the bioimpedance vector analysis (BIVA) could be a valid methodology to assess the fluid overload, whether there was a correlation between brain natriuretic peptide (BNP) and the fluid overload detected by BIVA, and whether this technique could be a valid guide in the management of the therapy in patients with acute decompensated heart failure (ADHF). A total of 51 patients arriving to the emergency department of the University Hospital Sant’Andrea (Rome, Italy) from December 2008 to April 2009 were enrolled. Hydration state, BNP, and caval index were evaluated at admission in the emergency department, at 24 and 72 hours, and at discharge. Vascular pedicle width was evaluated at admission and at discharge. BIVA values were correlated with BNP levels. A follow-up by phone at 3 months was performed. ADHF patients showed higher values of hydration state compared with controls. In ADHF patients, the difference between t 0 and t 72 BIVA mean values (P<.001) and between t 0 and discharge BIVA mean value (P<.0001) was statistically significant. Vascular pedicle width in ADHF patients showed a statistically significant difference (P<.0004) in compared with vascular pedicle width in controls. Congest Heart Fail. 2010;16(4)(suppl 1):S56–S61. ©2010 Wiley Periodicals, Inc.

Heart failure (HF) is associated with neurohumoral activation and abnormalities in autonomic control that lead to sodium and water retention and increased excretion of potassium, with subsequent edema or ascites.1 As a consequence, evaluation of hydration state is a relevant component in the assessment and treatment of patients in the emergency department (ED) with acute decompensated heart failure (ADHF).2

Although clinical assessment remains the mainstay of estimating the hydration state of patients with HF, it could be challenging to evaluate subtle hyperhydration or dehydration, which may result in increased short- and long-term morbidity. Consequently, the main goal of ED physicians is to distinguish immediately among (1) normal hydrated, (2) dehydrated, and (3) hyperhydrated patients.3–6 Thus, it is important to use an easy, reproducible, and noninvasive method for the estimation of fluid compartments.7,8

The bioimpedance vector analysis (BIVA) is a noninvasive technique to estimate body mass and water composition by bioelectrical impedance measurements, resistance, and reactance,9 which are already used in clinical practice for evaluating the fluid content in dialyzed patients.10 Brain natriuretic peptide (BNP) is an important biomarker released from the ventricles in response to wall stretch by increase in either volume or pressure during the acute phase of HF. Plasma concentrations of BNP correlate with symptomatic New York Heart Association (NYHA) class as well as prognosis in patients with systolic HF.11

The aim of this study was to verify whether BIVA could be a valid methodology to assess the fluid overload, whether there was a correlation between BNP and fluid overload detected by BIVA, and whether this technique coupled with BNP assessment could be a valid guide in the management of therapy in patients with ADHF.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Conclusions
  7. References

Patients

A total of 51 patients arriving to the ED of the University Hospital Sant’Andrea (Rome, Italy) from December 2008 to April 2009 were enrolled.

The patients were divided into 3 groups. Inclusion criteria for the first group (n=25) were acute respiratory distress (of at least 3 days), BNP level >500 pg/mL, clinical evidence of ADHF, and history of chronic HF with NYHA class 3 or 4 disease. The main characteristics were male/female, 11/4; age, 81±6 years; body mass index (BMI), 25±3 kg/m2; serum creatinine, 1.5±1 mg/dL; systolic blood pressure (SBP), 156±41 mm Hg; diastolic blood pressure (DBP), 85±26 mm Hg; heart rate (HR), 85±17 beats per minute; respiratory rate (RR), 23±7 breaths per minute; BNP, 1011.5±524.2 pg/mL; hydration, 79%±6%; and vascular pedicle width (VPW), 79±8 mm. Inclusion criteria for the second group (n=13) were acute respiratory distress (of at least 3 days), BNP level <400 pg/mL, no clinical evidence of ADHF, and every noncardiogenic dyspnea. The main characteristics were male/female, 7/6; age, 78±7 years; BMI, 26±5 kg/m2; serum creatinine, 1.5±1.3 mg/dL; SBP, 137±39 mm Hg; DBP, 70±8 mm Hg; HR, 87±23 beats per minute; RR, 26±6 breaths per minute; BNP, 235±72 pg/mL; hydration, 75%±47%; and VPW, 71±10 mm. The patients in the last group (n=13) had no clinical findings of cardiac or respiratory diseases and had BNP levels <100 pg/mL. The control group comprised this group together with group 2. The main characteristics were male/female, 6/7; age, 81±3 years; BMI, 25±2 kg/m2; serum creatinine, 1.2±0.2 mg/dL; SBP, 125±13 mm Hg; DBP, 70±5 mm Hg; HR 65±5 beats per minute; RR, 15±3 breaths per minute; BNP 20±22 pg/mL; hydration, 74%±2%; and VPW, 64±13 mm. Patients were stratified for sex, age, and BMI (Table I).

Table I.   Patient Characteristics
 Dyspnea and ADHF (n=25)Controls(n=26 Patients)
  1. Abbreviations: ADHF, acute decompensated heart failure; BMI, body mass index.

Sex, male/female11/1412/14
Age, y83±580±6
BMI, kg/m225±325±4

The exclusion criteria for each group were age younger than 18 years, thoracic and abdominal trauma, pneumothorax, past pneumonectomy, and invasive or noninvasive ventilation; pregnant women; patients unable to give written consent; and patients with intraperitoneal fluid, Glasgow Coma Scale <8, BMI >30 kg/m2, estimated glomerular filtration rate <60 mL/min, liver failure, constrictive pericarditis or cardiac tamponade, and exitus before 72 hours.

BIVA

In our study, the methodology used to analyze body fluids was BIVA, a noninvasive technique to estimate body mass and water composition by bioelectrical impedance measurements, resistance, and reactance.10 Resistance (R o Rz) is the strength opposed by a tissue to the electric current, conducted by electrolytes; fat-free tissues and fluids are good conductors, while bone tissue and fat tissues are bad conductors. Reactance (X o Xc) is due to the presence of inductors and/or electrolytic capacitors, and that is an indirect measure of cell membranes’ integrity.12,13 The arc tangent of Xc/R is called the phase angle. The patient lies supine, without metal contacts, with straddle inferior limbs at 45° and superior limbs abducted at 30° to avoid skin contacts with the trunk.12 Two skin electrodes are applied, one on the right hand and the other on the right foot. A minimal interelectrode distance of 5 cm has been recommended to prevent interaction between electrodes. The patient was laid recumbent on a nonconductive surface. Impedance measurements were taken independently from fasting as free fluid within the trunk (ascites, urine, food, or milk) does not contribute to the Xc component of impedance.

BIVA quickly evaluates body mass in normal, extremely obese, and undernourished patients and assesses the hydration state in normal (hydration, 72.7%/74.3%), hyperhydrated, and dehydrated patients by drawing a graphic (hydragram) representation of the results.14,15 BIVA shows Rz and Xc values adjusted for the patient’s height and plotted on the interpretative scheme, related to sex and age16 (Figure 1). Mean vector displacements in the RXc plane indicate a definite change in body composition of groups of patients, and 2 mean vectors with separate 95% confidence ellipses indicate a statistically significant difference in vector position on the RXc graph. Short vectors with a small phase angle are associated with edema, whereas long vectors with an increased phase angle indicate dehydration.17

image

Figure 1.  The bioimpedance vector analysis of hydration and nutrition status.

Download figure to PowerPoint

BIVA measurements were performed with electrofluidgraphy.18

VPW

As guidelines recommend, we performed the chest radiography as a diagnostic procedure to every dyspneic patient.19 This technique is used worldwide to evaluate lung congestion and also for differential diagnosis between cardiogenic and noncardiogenic dyspnea. Moreover, we evaluated VPW to obtain information about the volemic status of the patient.20 VPW was measured by dropping a perpendicular line from the point at which the left subclavian artery exits the aortic arch and measuring across to the point at which the superior vena cava crosses the right mainstem bronchus.21

Caval Index

Another noninvasive determination of fluid content used in our study was the caval index (CI).This parameter was acquired by an ultrasonographic assessment of vena cava dimensions. It was measured while patients were in the supine position. Inspiratory inferior vena cava and expiratory inferior vena cava diameters were measured 2 to 3 cm from the right atrial border in a long-axis/subxiphoid view with a 2- to 4-MHz curvilinear probe. Measurements were taken during a normal respiratory cycle; images were frozen on the ultrasonography machine and frame-by-frame analysis was performed to determine both expiratory inferior vena cava and inspiratory inferior vena cava values. The inferior vena cava and caval index was calculated as the relative decrease in inferior vena cava diameter during a normal respiratory cycle (expiratory inferior vena cava – inspiratory inferior vena cava / expiratory vena cava) and was also expressed as the inferior vena cava and CI percentage (inferior vena cava and CI × 100%).22 The relationship was the collapsibility index.23

BNP

A blood sample was collected for BNP measurement for all patients, as the literature24 has demonstrated that it is one of the most sensitive biomarkers to predict the prognosis and to make a rapid diagnosis of ADHF.25 BNP plasma concentration measurement was performed with the Triage BNP kit (Biosite, Inc, San Diego, CA), a single-use, ready-to-use, florescence immunoassay. A venous blood sample in an ethylenediaminetetraacetic acid tube was collected and measured in the Triage BNP tester.11

Hydration status, measured by BIVA, BNP, and CI, was evaluated at admission to the ED, at 24 and 72 hours, and at discharge. VPW was assessed only at admission and discharge. A phone call follow-up at 3 months was made to all discharged patients.

Statistical Analysis

All analyses were performed using MedCalc for Windows (release 10.4.8; MedCalc Software, Mariakerke, Belgium). Differences between 2 independent groups of continuous variables were compared using the Mann–Whitney U test. The correlation between BNP and BIVA was calculated using Spearman rank test. The correlation between urine output and BIVA was calculated using Spearman rank test. P values <.05 were considered significant. A receiver operating characteristic (ROC) curve assessing the ability of BIVA and VPW to predict events at 3 months was plotted.

Results

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Conclusions
  7. References

BIVA of ADHF patients at admission to the ED was compared with BIVA of controls, and the difference was statistically significant (P<.0007); ADHF patients had greater hydration (76.7%±4.0%) compared with controls (73.1%±1.9%). The hydration state of ADHF patients was evaluated at different points during hospitalization using BIVA. Baseline BIVA mean value at admission (t 0) was 76.74±4.0, BIVA mean value at 24 hours was 76.0±4.0, BIVA mean value at 72 hours was 75.3 ± 4.0, and BIVA mean value at discharge was 74.4±2.0. The difference between t 0 and t 72 BIVA mean values (P<.001) and between t 0 and discharge BIVA mean value (P<.0001) was statistically significant. The BIVA mean value in the control group was not statistically significant (P=.9372) (Figure 2). VPW in ADHF patients (77±7 mm) showed a statistically significant difference (P<.0004) compared with VPW in controls (48±5 mm). VPW mean values in ADHF patients on admission to the ED (77±7 mm) compared with VPW mean values at discharge (65±10 mm) were statistically significant (P=.003). As demonstrated by hydration state, there were no significant differences between VPW values at admission (48±5 mm) and at discharge in the control group (46±3 mm), showing no congestive state. CI in ADHF patients (29±20) showed a statistically significant difference (P=.02) compared with CI in controls (60±8). Baseline CI mean value at admission (t 0) was 29±20, CI mean value at 24 hours was 37±25, CI mean value at 72 hours was 42±24, and CI mean value at discharge was 51±17. CI mean values in ADHF patients on admission to the ED compared with mean values at discharge were statistically significant (P<.001).

image

Figure 2.  Effect of diuretic treatment in patients with acute decompensated heart failure: monitoring brain natriuretic peptide (BNP) and fluid content. Hydration state was analyzed at admission to the emergency department, 24 and 72 hours after admission, and at discharge, together with BNP and ultrasonographic measurement of the caval index and vascular pedicle width obtained through chest radiography. All the methods confirmed a good response to diuretic therapy with the shift of fluids from interstitial spaces. BIVA indicates bioimpedance vector analysis.

Download figure to PowerPoint

Values of BNP, BIVA, CI, and VPW at different considered times are shown in Figure 2.

Patients’ hydration state was immediately evaluated by BIA-Vector (Figure 3). The values' shift from a hyperhydrated state to a normal hydrated state showed improvement due to diuretic treatment in ADHF patients. BNP and BIVA at admission in ED were correlated in ADHF patients (Figure 4). The BIVA ROC curve showed a normal hydration state at 24 hours (Figure 5), with a specificity of 100% (area under the curve, 0.78; P=.04, 24 hours). In patients with average hydration values >80.5%, there was a correlation with events at 3 months (death or rehospitalization for cardiogenic event) with a sensitivity of 22% and specificity of 94.2% (+likelihood ratio [LR] 4.6 + predictive value [PV] 66.7 – PV 74.1). There was also a significant statistical value (r=.41; P=.01) between BNP and VPW (Table II).

image

Figure 3.  BIA-Vector: hydration in patients with acute decompensated heart failure (left panel) vs controls (right panel).24

Download figure to PowerPoint

image

Figure 4.  Correlation between brain natriuretic peptide (BNP) and bioimpedance vector analysis (BIVA) at admission to the emergency department (ED).

Download figure to PowerPoint

image

Figure 5.  Receiver operating characteristic curve of hydration state at 24 hours. BIA indicates bioimpedence analysis.

Download figure to PowerPoint

Table II.   Correlation With Events at 3 Months
  1. Abbreviations: LR, likelihood ratio; PV, predictive value.

 CutoffSensitivitySpecificity+LR+PV−PVP Value
BNP, pg/mL60060%70.3%2.055775.03
>90040%82.35%2.2762.5
BIVA, %>80.522%94%4.666.774.1.04
VPW, mm≤7092.865.223.1376.290.5.0001
>82.428.595.657.788.956.5

Moreover, VPW >82 mm has been correlated with events at 3 months (death or rehospitalization for cardiogenic events) with a sensitivity of 54% and specificity of 84.2% (+LR 3.4 + PV 66.7 – PV 76.2) (Figure 6). Furthermore, no statistically significant correlation was found with the other evaluated parameters for outcomes: sex, age, serum creatinine, blood pressure, HR, RR, and BMI.

image

Figure 6.  Receiver operating characteristic curve for events at 3 months correlated with vascular pedicle width >82 mm. AUC indicates area under the curve.

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Conclusions
  7. References

Currently, ADHF diagnosis is based on laboratory tests (complete blood cell count, sodium, potassium, glucose, blood urea nitrogen, serum creatinine, and arterial blood gas count and biomarkers such as troponin I and BNP),26,27 chest radiography, thoracic ultrasonography,28 respiratory variation of inferior vena cava diameter,29 echocardiography,30 and invasive hemodynamic monitoring. Most of these techniques are expensive, are not always available, and need time to be performed. In this setting, BIVA represents a valid, rapid, noninvasive, inexpensive technique in the evaluation of hydration state. In patients with hyperhydration due to ADHF, some studies have shown that reactance is strongly related to BNP values and NYHA severity class.31,32 Other studies have found a correlation between impedance and central venous pressure in critically ill patients.33 Our clinical experience with BIVA showed positive results when performed in ADHF patients admitted to the ED. Together with BIVA, we evaluated BNP34 and ultrasonographic measurement of CI and VPW obtained through chest radiography.35 Hydration state has been analyzed at admission to the ED, at 24 and 72 hours, and at discharge, and BIVA measurements have been correlated with the other 3 tests (Figure 2). Moreover, to distinguish cardiogenic dyspnea from noncardiogenic dyspnea, it is important to assess BNP values,36,37 which allow discriminating cardiogenic dyspnea for values >500 pg/mL.38 In our experience, the combined use of both BIVA and BNP improves diagnosis and therapeutic management in ADHF patients, maintaining the optimal hydration state through the correct use of diuretics (Figure 3 and Figure 4). As a matter of fact, the finding of elevated BNP levels coupled with BIVA short vector from admission to discharge leads the ED physician to a continuous and noninvasive evaluation of the fluid overload and allows appropriate management of diuretic therapy to prevent iatrogenic dehydration.

Our study also shows that VPW evaluation by chest radiography has very high specificity for values >80 mm to distinguish cardiogenic dyspnea from noncardiogenic dyspnea.

Unlike in ADHF patients, in the control group we found no statistically significant differences between hydration state values at admission to the ED and at discharge, showing the noncongestive state of patients with noncardiogenic dyspnea. These data are clearly described by the BIA-Vector (Figure 3).

In our preliminary results, BIVA and CI showed a significant and indirectly proportional correlation at admission to the ED and at 24 and 72 hours. These data confirm the strong correlation between hyperhydration and central venous congestion. The correlation between BIVA and urine output at 72 hours became directly proportional. It confirms a good response to diuretic therapy with the shift of fluids from interstitial spaces: the more patients were hyperhydrated, the more urine output was conspicuous. BIVA’s utility is confirmed by the ROC curve that shows a normal hydration state at 24 hours (Figure 5) and 72 hours, with a specificity of 100% (area under the curve, 0.78; P=.04, 24 hours; area under the curve, 0.9; P=.0001, 72 hours). The efficacy of diuretic therapy and the effectiveness of BIVA measurements were confirmed by normalization of BNP, VPW, and CI values at discharge (Figure 2). These results suggest that BIVA, more than clinical signs, could be useful to manage the diuretic therapy in ADHF patients in the ED. Therefore, there is a correlation with events at 3 months (death or rehospitalization for cardiogenic event) in patients with average hydration values >80.5% in the same way as there is in patients with VPW >82 mm.

Conclusions

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Conclusions
  7. References

The combined use of both BIVA and BNP improves the management of ADHF patients in the ED. It allows a faster and more accurate diagnosis, it is a valid support to distinguish cardiogenic dyspnea from noncardiogenic dyspnea, and it contributes to success in treatment. The combined use of both BIVA and BNP supports ED physicians’ decisions about diuretic therapy, preventing excessive dehydration. Moreover, BIVA was able to identify that patients with a higher percentage of hydration have more death and/or rehospitalization probabilities.

Disclosures:  The authors have no financial relationships with any commercial interests. Dr. Di Somma received an honorarium, funded by an unrestricted educational grant from Abbott Laboratories and Otsuka America Pharmaceuticals for time and expertise spent in preparation of this article.

References

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Conclusions
  7. References
  • 1
    Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coesistent chronic obstructive pulmunary disease and chronic hearth failure. J Am Coll Cardiol. 2007;49:171180.
  • 2
    Verbalis JG. Disorder of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17(4):471503.
  • 3
    Barbosa-Silva MC, Barros AJ. Bioelectrical impedance analysis in clinical practice: a new prospective on its use beyond body composition equations. Curr Opin Clin Nutr Metab Care. 2005;8(3):311317.
  • 4
    Nose H, Mack GW, Shi XR, Nadel ER. Shift in body fluid compartments after dehydration in humans. J Appl Physiol. 1988;65(1):318324.
  • 5
    Vincent JL, Weil MH. Fluid challenge revisited. Crit Care Med. 2006;34(5):13331337.
  • 6
    Kreimer U. Pathophysiology of fluid imbalance. Crit Care. 2000;4(Suppl. 2):S3S7.
  • 7
    Cotter G, Metra M, Milo-Cotter OG, et al. Fluid overload in acute heart failure - Re-distribution and other mechanism beyond fliud accumulation. Eur J Heart Fail. 2008;10(2):165169.
  • 8
    Martinez LC, Ramirez EC, Tejeda AO, et al. Bioelectrical impedance and strength measurements in patients with heart failure: comparison with functional class. Nutrition. 2007;23(5):412418.
  • 9
    Heymsfield SB, Wang ZM, Visser M, et al. Techniques used in the measurement of body composition: an overview with emphasis on bioelectrical impedance analysis. Am J Clin Nutr. 1996;64:478S484S.
  • 10
    Piccoli A. Bioelectric impedance vector distribution in peritoneal dialysis patients with different hydration status. Kidney Int. 2004;65(3):10501063.
  • 11
    Maisel A, Koon J, Krishaswamy P. Utility of B-natriuretic peptide as a rapid point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367374.
  • 12
    Kurshner RF. Bioelectrical impedance analysis: a review of principles and applications. J Am Coll Nutr. 1992;11(2):199209.
  • 13
    Talluri T. Fat-free mass qualitative assessment with bioelectric impedance analysis (BIA). Ann N Y Acad Sci. 1999;20:873894.
  • 14
    Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr. 1996;64: 489S497S.
  • 15
    Piccoli A, Nigrelli S, Caberlotto A, et al. Bivariate normal values of the bioelectrical impedance vector in adult and elderly populations. Am J Clin Nutr. 1995;61(2):269270.
  • 16
    Buffa R, Floris G, Marini E. Assessment of nutritional state in free living elderly individuals by bioelectrical impedance vector analysis. Nutrition. 2009;25(1):35.
  • 17
    Bozzetto S, Piccoli A, Montini G. Bioelectrical impedance vector analysis to evaluate relative hydration status. Pediatr Nephrol. 2010;25(2):329334.
  • 18
    Piccoli A, Rossi B, Pllon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the R/Xc graph. Kidney Int. 1994;46:534539.
  • 19
    Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933989.
  • 20
    Miller RR, Ely EW. Radiographic measures of intravascular volume status: the role pf vascular pedicle width. Curr Opin Crit Care. 2006;12(3):255262.
  • 21
    Studler U, Kretzschmar M, Christ M, et al. Accurancy of chest radiographs in the emergency diagnosis of heart failure. Eur Radiol. 2008;18:16441652.
  • 22
    Nagdev AD, Merchant RC, Tirado-Gonzalez A, et al. Emergency department bedside ultrasonographic measurement of the caval index for noninvasive determination of low central venous pressure. Ann Emerg Med. 2010;55(3):290295.
  • 23
    Moreno FL, Hagan AD, Holmen JR, et al. Evaluation of size and dynamics of the inferior vena cava as an index of right-sided cardiac function. Am J Cardiol. 1984;53:579585.
  • 24
    Maisel A, Di Somma S. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10(9):824839.
  • 25
    Daniels LB, Maisel AS. Ntriuretic peptides. J Am Coll Cardiol. 2007;50:23572368.
  • 26
    Chen WC, Tran KD, Maisel AS. Biomarkers in heart failure. Heart. 2010;96(4):314320.
  • 27
    Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36(Suppl. 1):S129S139.
  • 28
    Kataoka H, Takada S. The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure. J Am Coll Cardiol. 2000;35(6):16381646.
  • 29
    Bleahar DJ, Dickman E, Gaspari R. Identification of congestive heart failure via respiratory variation of inferior vena cava diameter. Am J Emerg Med. 2009;27:7175.
  • 30
    Nguyen HB, Losey T, Rasmussen J, et al. Interrater reliability of cardiac output measurements by transcutaneous Doppler ultrasound: implications for noninvasive hemodynamic monitoring in the ED. Am J Emerg Med. 2006;24(7):828835.
  • 31
    Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol. 2009;24(2):155160.
  • 32
    Müller C, Kuster G, Büttner HJ, Buser P. B-type natriuretic peptide–current use in the diagnosis and management of heart failure. Herz. 2003;28(5):374379.
  • 33
    Piccoli A, Pittoni G, Facco E, et al. Relationship between central venous pressure and bioimpedance vector analysis in critically ill patients. Crit Care Med. 2000;28(1):132137.
  • 34
    Muller C. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166:10811087.
  • 35
    Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10(5 Suppl. 3):130.
  • 36
    Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37(2):386391.
  • 37
    Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37(2):379385.
  • 38
    Maisel A. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161167.